These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

324 related articles for article (PubMed ID: 17706529)

  • 1. F-18 fluorodeoxyglucose-positron emission tomography imaging for primary breast cancer and loco-regional staging.
    Avril N; Adler LP
    Radiol Clin North Am; 2007 Jul; 45(4):645-57, vi. PubMed ID: 17706529
    [TBL] [Abstract][Full Text] [Related]  

  • 2. F-18 Fluorodeoxyglucose-Positron Emission Tomography Imaging for Primary Breast Cancer and Loco-Regional Staging.
    Avril N; Adler LP
    PET Clin; 2006 Jan; 1(1):1-13. PubMed ID: 27156954
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Positron emission tomography for the diagnosis of breast cancer.
    Rosé C; Dose J; Avril N
    Nucl Med Commun; 2002 Jul; 23(7):613-8. PubMed ID: 12089482
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PET imaging in breast cancer.
    Bombardieri E; Crippa F
    Q J Nucl Med; 2001 Sep; 45(3):245-56. PubMed ID: 11788817
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prospective multicenter study of axillary nodal staging by positron emission tomography in breast cancer: a report of the staging breast cancer with PET Study Group.
    Wahl RL; Siegel BA; Coleman RE; Gatsonis CG;
    J Clin Oncol; 2004 Jan; 22(2):277-85. PubMed ID: 14722036
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 18-Fluorodeoxyglucose-positron emission tomography in inflammatory breast cancer.
    Baslaim MM; Bakheet SM; Bakheet R; Ezzat A; El-Foudeh M; Tulbah A
    World J Surg; 2003 Oct; 27(10):1099-104. PubMed ID: 12917770
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical application of 18F-fluoro-2-deoxy-D-glucose positron emission tomography/computed tomography in breast cancer.
    Bernsdorf M; Graff J
    Clin Physiol Funct Imaging; 2014 Nov; 34(6):426-33. PubMed ID: 24267489
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The value of F-18 fluorodeoxyglucose in positron emission tomography diagnosis of breast carcinoma].
    Langsteger W; Jörg L; Tausch C; Heinisch M; Wieser B; Rechberger E; Panholzer PJ; Sega W; Aufschnaiter M
    Wien Med Wochenschr; 2002; 152(11-12):255-8. PubMed ID: 12138651
    [TBL] [Abstract][Full Text] [Related]  

  • 9. F-18 fluorodeoxyglucose positron-emission tomography in the diagnosis of tumor recurrence and metastases in the follow-up of patients with breast carcinoma: a comparison to conventional imaging.
    Gallowitsch HJ; Kresnik E; Gasser J; Kumnig G; Igerc I; Mikosch P; Lind P
    Invest Radiol; 2003 May; 38(5):250-6. PubMed ID: 12750613
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Possible uses of positron emission tomography in breast carcinoma].
    Römer W; Avril N; Schwaiger M
    Acta Med Austriaca; 1997; 24(2):60-2. PubMed ID: 9273807
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Fluorodeoxyglucose-PET in the management of breast cancer.
    Kumar R; Alavi A
    Radiol Clin North Am; 2004 Nov; 42(6):1113-22, ix. PubMed ID: 15488561
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Lymph node staging of gastric cancer using (18)F-FDG PET: a comparison study with CT.
    Yun M; Lim JS; Noh SH; Hyung WJ; Cheong JH; Bong JK; Cho A; Lee JD
    J Nucl Med; 2005 Oct; 46(10):1582-8. PubMed ID: 16204706
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Detection of breast cancer in an FDG-PET cancer screening program: results of a nationwide Japanese survey.
    Minamimoto R; Senda M; Jinnouchi S; Terauchi T; Yoshida T; Inoue T
    Clin Breast Cancer; 2015 Apr; 15(2):e139-46. PubMed ID: 25454690
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inefficacy of F-18 fluorodeoxy-D-glucose-positron emission tomography scans for initial evaluation in early-stage cutaneous melanoma.
    Wagner JD; Schauwecker D; Davidson D; Logan T; Coleman JJ; Hutchins G; Love C; Wenck S; Daggy J
    Cancer; 2005 Aug; 104(3):570-9. PubMed ID: 15977211
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Positron emission tomography in diagnosis and management of invasive breast cancer: current status and future perspectives.
    Wu D; Gambhir SS
    Clin Breast Cancer; 2003 Apr; 4 Suppl 1():S55-63. PubMed ID: 12756080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Role of positron emission tomography/computed tomography in breast cancer.
    Bourgeois AC; Warren LA; Chang TT; Embry S; Hudson K; Bradley YC
    Radiol Clin North Am; 2013 Sep; 51(5):781-98. PubMed ID: 24010906
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Diagnosis of recurrent and metastatic disease using f-18 fluorodeoxyglucose-positron emission tomography in breast cancer.
    Eubank WB
    Radiol Clin North Am; 2007 Jul; 45(4):659-67, vi. PubMed ID: 17706530
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Evaluation of the internal mammary lymph nodes by FDG-PET in locally advanced breast cancer (LABC).
    Bellon JR; Livingston RB; Eubank WB; Gralow JR; Ellis GK; Dunnwald LK; Mankoff DA
    Am J Clin Oncol; 2004 Aug; 27(4):407-10. PubMed ID: 15289736
    [TBL] [Abstract][Full Text] [Related]  

  • 19. FDG PET, PET/CT, and breast cancer imaging.
    Rosen EL; Eubank WB; Mankoff DA
    Radiographics; 2007 Oct; 27 Suppl 1():S215-29. PubMed ID: 18180228
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [FDG-PET (positron emission tomography) in the detection of primary breast cancer and lymph node involvement].
    Koga S; Nakano S; Honma Y; Ogasawara N
    Nihon Rinsho; 2007 Jun; 65 Suppl 6():379-84. PubMed ID: 17682181
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 17.